Acquired L718V/ co-mutation and discordant molecular pattern between plasmatic and cerebrospinal fluid in a bone and meningeal metastatic L858R+ non-small cell lung cancer: a case report.

Date publication

mars 2023

Journal

Annals of translational medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr PENCREACH Erwan , Dr GANTZER Justine , Dr BENDER Laura

Tous les auteurs :
Schultz É, Pencreach E, Rimelen V, Palama A, Holder É, Gantzer J, Bender L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37007549

Résumé

Osimertinib is approved in first line metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). Acquired L718V mutation is a rare mechanism of resistance towards osimertinib in L858R+ NSCLC with potential sensibility to afatinib. This case reported an acquired L718V/TP53 V727M resistance co-mutation to osimertinib with discordant molecular pattern between plasmatic and cerebral fluid in a leptomeningeal and bone metastatic L858R mutant NSCLC.

Mots clés

EGFR L718V mutation, Osimertinib, case report, leptomeningeal metastasis, non-small cell lung carcinoma

Référence

Ann Transl Med. 2023 03 15;11(5):223